NBIX - Neurocrine Bio sees Ingrezza sales of $993M in FY20

Neurocrine Biosciences (NBIX) updates on preliminary Ingrezza (valbenazine) sales for 2020, and key 2021 milestones.Q4 and FY20 Ingrezza net product sales are expected to be ~$240M and $993M, respectively.Ingrezza inventory adjusted net product sales for Q4 were ~$258M.FY20 total INGREZZA prescriptions grew 32% to ~175,700 vs. ~132,700 in 2019."Adding to our movement disorder portfolio, we launched our second commercial treatment, ONGENTYS, and continue to make great progress in our development programs with plans to initiate seven mid-to-late stage clinical studies in 2021 focused on neurological, endocrine and psychiatric disorders," said Kevin Gorman, Ph.D., CEO.

For further details see:

Neurocrine Bio sees Ingrezza sales of $993M in FY20